Page last updated: 2024-10-27

furazolidone and Leishmaniasis, Visceral

furazolidone has been researched along with Leishmaniasis, Visceral in 1 studies

Furazolidone: A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
furazolidone : A member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera.

Leishmaniasis, Visceral: A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tempone, AG1
Mortara, RA1
de Andrade, HF1
Reimão, JQ1

Other Studies

1 other study available for furazolidone and Leishmaniasis, Visceral

ArticleYear
Therapeutic evaluation of free and liposome-loaded furazolidone in experimental visceral leishmaniasis.
    International journal of antimicrobial agents, 2010, Volume: 36, Issue:2

    Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Cricetinae; Drug Delivery Systems; Drug Evaluation,

2010